Hamid Bolouri, PhD, named Associate Member in the Center for Systems Immunology at Benaroya Research Institute at Virginia Mason
Bolouri’s research focus will be the development and use of machine learning, bioinformatics and other statistical/mathematical methods to integrate data types into network models of immune cells. The models help illustrate how real human immune cells work, both in normal function and in dysfunction.
BRI’s Center for Systems Immunology analyzes large and complex data sets to identify patterns that may accelerate discovery and disease breakthroughs.
"I am pleased that Dr. Bolouri has agreed to join the BRI faculty," said Jane Buckner, MD, president of BRI. "I believe he will be a wonderful addition to our Systems Immunology group and I am looking forward to seeing how he can help us think about our data in new ways," she said.
Dr. Bolouri received his PhD from Brunel University (London) and was a faculty member at the University of Hertfordshire. In 2002, he joined the Institute for Systems Biology in Seattle as a Professor of Computational Biology and in 2010, the Division of Human Biology at Fred Hutchinson Cancer Research Center (Seattle) as a Research Full Member. Before joining BRI, he was Director of Informatics & Computational Biology at the Allen Institute for Immunology.
About Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI) is a world-renowned, non-profit research institute committed to advancing the science that will predict, prevent, reverse and cure diseases of the immune system. BRI researchers uniquely study the immune system in both health and disease, with the ultimate goal of achieving a healthy immune system for each individual. Diseases we study include type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis, Crohn’s and colitis as well as allergies and cancer. BRI accelerates discovery through laboratory breakthroughs in immunology that can be translated to clinical therapies. A leader of collaborative initiatives such as the Immune Tolerance Network and Type 1 Diabetes TrialNet, BRI frequently partners with global research institutes, pharmaceutical and biotech companies.
Christi B. Nichols
Marketing Communications & External Relations
firstname.lastname@example.org / 206-342-6519